Table 4.
Comparison of breast cancer-specific survival (BCSS) and overall survival (OS) between matched patients with chemotherapy and no-chemotherapy in specific stage
| Stage | BCSS | OS | ||||
|---|---|---|---|---|---|---|
| Events No | HRs (95%CI) | P a | Events No | HRs (95%CI) | P a | |
| Stage I ( n = 1,312) | 53 | 0.932 | 103 | 0.111 | ||
| Chemotherapy | 1.024(0.595–1.764) | 0.723(0.485–1.078)* | ||||
| No-Chemotherapy | Reference | Reference | ||||
| Stage II ( n = 985) | 164 | 0.001 | 247 | < 0.001 | ||
| Chemotherapy | 0.564(0.408–0.779) | 0.522(0.400–0.682)* | ||||
| No-Chemotherapy | Reference | Reference | ||||
| Stage III ( n = 363) | 142 | 0.001 | 192 | < 0.001 | ||
| Chemotherapy | 0.549(0.386–0.781) | 0.537(0.395–0.728)* | ||||
| No-Chemotherapy | Reference | Reference | ||||
| Stage I-III ( n = 2,660) | 359 | < 0.001 | 542 | < 0.001 | ||
| Chemotherapy | 0.612(0.493–0.759)* | 0.549(0.459–0.655)* | ||||
| No-Chemotherapy | Reference | Reference | ||||
Abbreviation: HR Hazard ratio, CI Confidence interval, BCSS Breast cancer-specific survival, OS Overall survival, Events No Number of events
aP value was adjusted by a multivariate Cox proportional hazard regression model or a time-dependent covariate analysis. Bold type indicates significance
bThe groups using time-dependent covariate analysis were specifically marked with asterisks(*)